Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beth-Ann Coller

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Vaccine|October 28, 2006
Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitisDouglas M Watts, Robert B Tesh, Marina Siirin, et al.
Clinical and Vaccine Immunology : CVI|July 31, 2009
Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeysMichael M Lieberman, Vivek R Nerurkar, Haiyan Luo, et al.
Human Vaccines & Immunotherapeutics|November 15, 2018
Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adultsSusan B Manoff, Michele Sausser, Amy Falk Russell, et al.
The Lancet. Microbe|May 11, 2022
Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trialsRebecca F Grais, Stephen B Kennedy, Barbara E Mahon, et al.
Vaccine: X|August 7, 2019
rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessmentThomas P Monath, Patricia E Fast, Kayvon Modjarrad, et al.
Cell Reports|April 16, 2023
Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primatesBronwyn M Gunn, Ryan P McNamara, Lianna Wood, et al.
Vaccine|September 26, 2006
Preparation and immunogenic properties of a recombinant West Nile subunit vaccineMichael M Lieberman, David E Clements, Steven Ogata, et al.
The American Journal of Tropical Medicine and Hygiene|May 13, 2020
Immunogenicity and Safety of a Tetravalent Recombinant Subunit Dengue Vaccine in Adults Previously Vaccinated with a Live Attenuated Tetravalent Dengue Vaccine: Results of a Phase-I Randomized Clinical TrialAnna P Durbin, Kristen K Pierce, Beth D Kirkpatrick, et al.
Emerging Microbes & Infections|March 15, 2021
High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmissionIgor Morozov, Thomas P Monath, David A Meekins, et al.
Vaccine|July 12, 2005
An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque modelJ Robert Putnak, Beth-Ann Coller, Gerald Voss, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Vaccine|October 28, 2006
Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitisDouglas M Watts, Robert B Tesh, Marina Siirin, et al.
Clinical and Vaccine Immunology : CVI|July 31, 2009
Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeysMichael M Lieberman, Vivek R Nerurkar, Haiyan Luo, et al.
Human Vaccines & Immunotherapeutics|November 15, 2018
Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adultsSusan B Manoff, Michele Sausser, Amy Falk Russell, et al.
The Lancet. Microbe|May 11, 2022
Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trialsRebecca F Grais, Stephen B Kennedy, Barbara E Mahon, et al.
Vaccine: X|August 7, 2019
rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessmentThomas P Monath, Patricia E Fast, Kayvon Modjarrad, et al.
Cell Reports|April 16, 2023
Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primatesBronwyn M Gunn, Ryan P McNamara, Lianna Wood, et al.
Vaccine|September 26, 2006
Preparation and immunogenic properties of a recombinant West Nile subunit vaccineMichael M Lieberman, David E Clements, Steven Ogata, et al.
The American Journal of Tropical Medicine and Hygiene|May 13, 2020
Immunogenicity and Safety of a Tetravalent Recombinant Subunit Dengue Vaccine in Adults Previously Vaccinated with a Live Attenuated Tetravalent Dengue Vaccine: Results of a Phase-I Randomized Clinical TrialAnna P Durbin, Kristen K Pierce, Beth D Kirkpatrick, et al.
Emerging Microbes & Infections|March 15, 2021
High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmissionIgor Morozov, Thomas P Monath, David A Meekins, et al.
Vaccine|July 12, 2005
An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque modelJ Robert Putnak, Beth-Ann Coller, Gerald Voss, et al.
Pageof 2